Is Oric Pharmaceuticals Stock a Good Investment?
Oric Pharmaceuticals Investment Advice | ORIC |
- Examine Oric Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Oric Pharmaceuticals' leadership team and their track record. Good management can help Oric Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Oric Pharmaceuticals' business and its evolving consumer preferences.
- Compare Oric Pharmaceuticals' performance and market position to its competitors. Analyze how Oric Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Oric Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Oric Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Oric Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Oric Pharmaceuticals is a good investment.
Sell | Buy |
Sell
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Oric Pharmaceuticals Stock
Researching Oric Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 91.0% of the company shares are owned by institutional investors. The book value of Oric Pharmaceuticals was now reported as 3.88. The company recorded a loss per share of 1.82. Oric Pharmaceuticals had not issued any dividends in recent years.
To determine if Oric Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oric Pharmaceuticals' research are outlined below:
| Oric Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (100.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oric Pharmaceuticals currently holds about 227.06 M in cash with (85.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Oric Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Kunkel Lori Anne of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3 |
Oric Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oric Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oric Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Oric Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Oric Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-06 | 2024-03-31 | -0.44 | -0.37 | 0.07 | 15 | ||
2023-08-10 | 2023-06-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2022-11-07 | 2022-09-30 | -0.55 | -0.63 | -0.08 | 14 | ||
2021-08-10 | 2021-06-30 | -0.49 | -0.57 | -0.08 | 16 | ||
2022-08-11 | 2022-06-30 | -0.6 | -0.51 | 0.09 | 15 | ||
2021-11-08 | 2021-09-30 | -0.58 | -0.47 | 0.11 | 18 | ||
2020-08-05 | 2020-06-30 | -0.4 | -0.51 | -0.11 | 27 | ||
2021-03-23 | 2020-12-31 | -0.46 | -0.84 | -0.38 | 82 |
Oric Pharmaceuticals Target Price Consensus
Oric target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Oric Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Oric analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Oric stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Oric Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOric Pharmaceuticals Target Price Projection
Oric Pharmaceuticals' current and average target prices are 10.42 and 18.73, respectively. The current price of Oric Pharmaceuticals is the price at which Oric Pharmaceuticals is currently trading. On the other hand, Oric Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Oric Pharmaceuticals Market Quote on 1st of February 2025
Target Price
Analyst Consensus On Oric Pharmaceuticals Target Price
Oric Pharmaceuticals Analyst Ratings
Oric Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Oric Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Oric Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Oric Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Oric Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oric Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oric Pharmaceuticals backward and forwards among themselves. Oric Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oric Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Llc | 2024-09-30 | 1.7 M | Nea Management Company, Llc | 2024-09-30 | 1.5 M | First Turn Management Llc | 2024-09-30 | 1.5 M | Avidity Partners Management Lp | 2024-09-30 | 1.4 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | Vivo Capital, Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Balyasny Asset Management Llc | 2024-09-30 | 1.1 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 1.1 M | Nextech Invest Ag | 2024-09-30 | 5.3 M | Blackrock Inc | 2024-09-30 | 5.1 M |
Oric Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 760.01 M.Market Cap |
|
Oric Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.52) | (0.54) |
Determining Oric Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Oric Pharmaceuticals is a good buy. For example, gross profit margin measures Oric Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oric Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Oric Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oric Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oric Pharmaceuticals' management manipulating its earnings.
Evaluate Oric Pharmaceuticals' management efficiency
Oric Pharmaceuticals has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4598) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 1, 2025, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Oric Pharmaceuticals' Debt To Assets are projected to increase slightly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.92 | 3.52 | |
| Tangible Book Value Per Share | 3.92 | 3.54 | |
| Enterprise Value Over EBITDA | (3.77) | (3.96) | |
| Price Book Value Ratio | 2.43 | 2.31 | |
| Enterprise Value Multiple | (3.77) | (3.96) | |
| Price Fair Value | 2.43 | 2.31 | |
| Enterprise Value | 529.2 M | 581.3 M |
The operational strategies employed by Oric Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.122 |
Basic technical analysis of Oric Stock
As of the 1st of February, Oric Pharmaceuticals holds the Risk Adjusted Performance of 0.0914, semi deviation of 4.22, and Coefficient Of Variation of 1004.51. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oric Pharmaceuticals, as well as the relationship between them.Oric Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oric Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oric Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oric Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oric Pharmaceuticals' Outstanding Corporate Bonds
Oric Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oric Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oric bonds can be classified according to their maturity, which is the date when Oric Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View | |
| US68622TAB70 Corp BondUS68622TAB70 | View | |
| US68622TAA97 Corp BondUS68622TAA97 | View |
Understand Oric Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Oric Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0914 | |||
| Market Risk Adjusted Performance | 0.3249 | |||
| Mean Deviation | 3.71 | |||
| Semi Deviation | 4.22 | |||
| Downside Deviation | 4.7 | |||
| Coefficient Of Variation | 1004.51 | |||
| Standard Deviation | 4.9 | |||
| Variance | 23.99 | |||
| Information Ratio | 0.0792 | |||
| Jensen Alpha | 0.3413 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0826 | |||
| Treynor Ratio | 0.3149 | |||
| Maximum Drawdown | 22.87 | |||
| Value At Risk | (6.91) | |||
| Potential Upside | 8.04 | |||
| Downside Variance | 22.06 | |||
| Semi Variance | 17.78 | |||
| Expected Short fall | (3.95) | |||
| Skewness | 0.1255 | |||
| Kurtosis | 1.09 |
| Risk Adjusted Performance | 0.0914 | |||
| Market Risk Adjusted Performance | 0.3249 | |||
| Mean Deviation | 3.71 | |||
| Semi Deviation | 4.22 | |||
| Downside Deviation | 4.7 | |||
| Coefficient Of Variation | 1004.51 | |||
| Standard Deviation | 4.9 | |||
| Variance | 23.99 | |||
| Information Ratio | 0.0792 | |||
| Jensen Alpha | 0.3413 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0826 | |||
| Treynor Ratio | 0.3149 | |||
| Maximum Drawdown | 22.87 | |||
| Value At Risk | (6.91) | |||
| Potential Upside | 8.04 | |||
| Downside Variance | 22.06 | |||
| Semi Variance | 17.78 | |||
| Expected Short fall | (3.95) | |||
| Skewness | 0.1255 | |||
| Kurtosis | 1.09 |
Consider Oric Pharmaceuticals' intraday indicators
Oric Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oric Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 10.42 | |||
| Day Typical Price | 10.42 | |||
| Price Action Indicator | (0.17) | |||
| Period Momentum Indicator | (0.35) |
Oric Pharmaceuticals Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Oric Stock media impact
Far too much social signal, news, headlines, and media speculation about Oric Pharmaceuticals that are available to investors today. That information is available publicly through Oric media outlets and privately through word of mouth or via Oric internal channels. However, regardless of the origin, that massive amount of Oric data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oric Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oric Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oric Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oric Pharmaceuticals alpha.
Oric Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Oric Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Oric Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA BA | CoFounder Board | Profile | |
| Lori Friedman | Chief Officer | Profile | |
| Esq JD | G Counsel | Profile | |
| MS MD | Chief Officer | Profile | |
| Matthew Panuwat | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Oric Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.